Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
Esperion (NASDAQ: ESPR) will host a virtual Key Opinion Leader event on Tuesday, November 11, 2025 at 2:00 p.m. ET to discuss clinical and real-world challenges of statin intolerance and impacts on patient outcomes. The event is led by LeAnne Bloedon, VP, Head of Clinical Development, and features experts including Fatima Rodriguez, MD, MPH, and Dharmesh S. Patel, MD.
The company highlighted that nearly 20% of patients discontinue statins within one year and emphasized dialogue on strategies—including bempedoic acid therapies. A live audio webcast and replay (available ~2 hours after the call) will be posted on the investor section of the Esperion website and archived for ~90 days.
Esperion (NASDAQ: ESPR) terrà un evento virtuale per Leader di opinione chiave il martedì 11 novembre 2025 alle 14:00 ET per discutere le sfide cliniche e del mondo reale legate all'intolleranza ai statine e gli impatti sugli esiti dei pazienti. L'evento è guidato da LeAnne Bloedon, VP, Responsabile dello Sviluppo Clinico, e vede tra i relatori Fatima Rodriguez, MD, MPH, e Dharmesh S. Patel, MD.
L'azienda ha evidenziato che quasi il 20% dei pazienti interrompe l'uso delle statine entro un anno e ha sottolineato il dialogo su strategie, tra cui le terapie a base di acido bempedoico. La trasmissione audio in diretta e la replica (disponibile circa 2 ore dopo la chiamata) saranno pubblicate nella sezione investitori del sito Esperion e resteranno arhivi per circa 90 giorni.
Esperion (NASDAQ: ESPR) organizará un evento virtual de Líder de Opinión Clave el martes 11 de noviembre de 2025 a las 2:00 p.m. Hora del Este para discutir los desafíos clínicos y del mundo real de la intolerancia a las estatinas y sus impactos en los resultados de los pacientes. El evento lo dirige LeAnne Bloedon, VP, Jefa de Desarrollo Clínico, y contará con expertos como Fatima Rodriguez, MD, MPH, y Dharmesh S. Patel, MD.
La empresa destacó que casi el 20% de los pacientes interrumpe las estatinas dentro de un año y enfatizó el diálogo sobre estrategias, incluidas las terapias con ácido bempedoico. Una transmisión de audio en vivo y una repetición (disponible aproximadamente 2 horas después de la llamada) se publicarán en la sección de inversores del sitio web de Esperion y quedarán archivadas por unos 90 días.
Esperion(NASDAQ: ESPR)은 2025년 11월 11일 화요일 오후 2:00(동부표준시)에 가상 주요 의견 리더 이벤트를 개최하여 스타틴 불내증의 임상적·현실적 도전과 환자 결과에 대한 영향에 대해 논의합니다. 이 행사는 LeAnne Bloedon, VP, 임상 개발 책임자가 이끌며 Fatima Rodriguez, MD, MPH, Dharmesh S. Patel, MD 등의 전문가가 참여합니다.
회사는 거의 20%의 환자가 1년 이내에 스타틴을 중단한다는 점을 강조하고; bempedoic 산의 요법을 포함한 전략에 대한 대화를 강조했습니다. 라이브 오디오 웹캐스트와 재방송(통화 후 약 2시간 후 이용 가능)은 Esperion 웹사이트의 투자자 섹션에 게시되며 약 90일 동안 보관됩니다.
Esperion (NASDAQ : ESPR) organisera un événement virtuel de Leader d’opinion clé le mardi 11 novembre 2025 à 14h00, heure de l’Est pour discuter des défis cliniques et réels de l’intolérance aux statines et de leurs impacts sur les résultats des patients. L’événement est dirigé par LeAnne Bloedon, vice-présidente, responsable du développement clinique, et réunit des experts dont Fatima Rodriguez, MD, MPH, et Dharmesh S. Patel, MD.
L’entreprise a souligné que presque 20 % des patients interrompent les statines dans l’année et a mis l’accent sur le dialogue sur les stratégies – y compris les thérapies à l’acide bempédique. Une diffusion audio en direct et une rediffusion (disponible environ 2 heures après l’appel) seront publiées dans la section investisseurs du site Web d’Esperion et seront archivées pendant environ 90 jours.
Esperion (NASDAQ: ESPR) wird am Dienstag, dem 11. November 2025, um 14:00 Uhr ET eine virtuelle Key Opinion Leader-Veranstaltung abhalten, um klinische und reale Herausforderungen der Statin-Intoleranz und Auswirkungen auf die Patientenergebnisse zu diskutieren. Die Veranstaltung wird von LeAnne Bloedon, VP, Leiterin der klinischen Entwicklung, geleitet und Experten wie Fatima Rodriguez, MD, MPH, und Dharmesh S. Patel, MD, gehören dazu.
Das Unternehmen hob hervor, dass fast 20 % der Patienten innerhalb eines Jahres Statine absetzen, und betonte den Dialog über Strategien – einschließlich Therapien mit dem Bempedoinsäure-Wirkstoff. Ein Live-Audio-Webcast und eine Wiederholung (verfügbar ca. 2 Stunden nach dem Anruf) werden im Investorenbereich der Esperion-Website veröffentlicht und ca. 90 Tage lang archiviert.
ستعقد Esperion (ناسداك: ESPR) حدثًا افتراضيًا لقائد رأي رئيسي يوم الثلاثاء 11 نوفمبر 2025 الساعة 2:00 مساءً بتوقيت شرق الولايات المتحدة لمناقشة التحديات السريرية والواقعية لحساسية الستاتين وتأثيرها على نتائج المرضى. يقوده ليان بلودون، نائب الرئيس ورئيس التطوير السريري، ويضم خبراء مثل فاطمة رودريغيز، MD، MPH، ودهارميش س. باتل، MD.
أبرزت الشركة أن قرابة 20٪ من المرضى يوقفون استخدام الستاتينات خلال عام، وأكدت الحوار حول الاستراتيجيات - بما فيها علاجات تحتوي على حمض بيمبدويك. سيُبث الحدث صوتيًا حيًا وتتوفر إعادة بث (بعد حوالي ساعتين من المكالمة)، وسيتم نشر المحتوى في قسم المستثمرين بموقع Esperion الإلكتروني وأرشفته لمدة نحو 90 يومًا.
Esperion (纳斯达克: ESPR) 将于 2025年11月11日星期二美国东部时间下午2:00 举办一场虚拟的关键意见领袖活动，讨论曲线临床和真实世界中的他汀类药物耐受性的挑战及其对患者结局的影响。该活动由 LeAnne Bloedon, VP, 负责临床开发 主导，特邀专家包括 Fatima Rodriguez, MD, MPH，以及 Dharmesh S. Patel, MD。
该公司强调 将近20% 的患者在一年内停止使用他汀类药物，并强调关于策略的对话——包括含有贝姆哚酸的疗法。此次活动将有现场音频网络直播及回放（在通话后大约2小时可用），相关内容将发布在 Esperion 网站的投资者板块，并大约保存90天。
- None.
- None.
– Leading Cardiovascular Physician Experts to Explore Real-World Challenges and Impact on Patient Outcomes –
ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event for investors to discuss the clinical and real-world challenges of statin intolerance, its impact on patient outcomes, and the Company’s continued commitment to addressing this significant unmet need.
The event will be led by LeAnne Bloedon, VP, Head of Clinical Development at Esperion and will feature a discussion with:
- Fatima Rodriguez, MD, MPH, Section Chief of Preventive Cardiology, Vice Chair of Clinical Research in the Department of Medicine, and Associate Director of the Stanford Center for Digital Health
- Dharmesh S. Patel, MD, FACC, MBBS (Lon), FACP, FASPC, FNLA, RVPI, Lipid Director Stern Cardiovascular Foundation Memphis, TN, Clinical Professor of Cardiology at the Baptist University College of Osteopathic Medicine, Memphis Director Cardiac Rehabilitation, Baptist Desoto Hospital
“Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, and the need for innovative solutions is urgent. Our research shows that nearly
Registration for the KOL webinar can be found here. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is the Esperion (ESPR) virtual KOL event on statin intolerance?
Who will lead the Esperion (ESPR) KOL webinar on November 11, 2025?
How can investors access the Esperion (ESPR) webcast and replay?
What statin intolerance statistic did Esperion (ESPR) cite for the KOL event?
Will the Esperion (ESPR) KOL event discuss bempedoic acid therapies?
Is registration required to join the Esperion (ESPR) November 11, 2025 webinar?
